64cu-DOTA-Anti-CD33 PET-CT Imaging for Acute Myeloid Leukemia and Image-Guided Treatment

Conclusion:This study is the first to use an anti-CD33 monoclonal antibody for non-invasive immuno-PET-based imaging for AML detection, showing high sensitivity and specificity. This whole body imaging may be useful for AML diagnosis not only in the entire skeletal system, but also in the extramedullary organs, and for longitudinal monitoring of treatment response. Unlike conventional TBI, Image-guided fTMI along with conventional chemotherapy may result in an improved prognosis, as unintended major organs are spared from radiation.DisclosuresVallera: GT Biopharma: Consultancy, Research Funding. Stein: Celgene: Speakers Bureau; Amgen Inc.: Speakers Bureau.

Source: Blood - November 21, 2018 Category: Hematology Authors: Sargur Madabushi, S., Zuro, D., Brooks, J., Kumar, B., E Parra, L., Orellana, M., Nair, I., Chea, J., Poku, K., Chen, C.-C., Sanchez, J., Shively, J. E., Vallera, D. A., Wong, J., Stein, A. S., Colcher, D., Yazaki, P., Hui, S. Tags: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II Source Type: research